The government is making a new push into the biotechnology sector by investing in a company that will focus on the development of a drug for treating AIDS.
The state-owned National Development Fund (NDF) will pump in US$20 million to help establish a biotech firm to be called TaiMed Biologics, Council for Economic Planning and Development Chairwoman Ho Mei-yueh (何美玥) told a press conference yesterday.
The move is one of a package of government measures designed to turn the nation's biotech industry into a trillion-dollar sector, following in the footsteps of the foundry and display industries.
PHOTO: CHEN TSE-MING, TAIPEI TIMES
Of the NT$30 billion (US$907 million) budget the government plans to invest in the biotech sector, the state fund has directly invested NT$8 billion in 12 biotech companies, Ho said, adding that the government could pump in more capital to fuel the industry's growth even after the budget is expended.
The new biotech company will be chaired by former vice premier Tsai Ying-wen (
David Ho told the press conference that, although it was impossible to know whether the NDF would see significant returns from its investment in TaiMed Biologics, this kind of investment is needed to stimulate the industry.
TaiMed Biologics purchased the patent for the drug TNX-355, which was developed by US-based Genentech Inc, and plans to complete development of the drug, which blocks HIV from entering human cells, in three years.
After launching TNX-355 on the global market, TaiMed Biologics will devote itself to developing flu and bird flu vaccines, he said.
If TaiMed Biologics later establishes a plant to manufacture drugs or other medical products, the NDF would also finance that, Ho Mei-yueh said.
Inviting private enterprises to jointly invest in TaiMed Biologics, the CEPD chairwoman said she had a shortlist of possible investors and would first approach Terry Gou (郭台銘), chairman of Hon Hai Precision Industry Co (鴻海精密).
On Sept. 4, Gou announced he would donate NT$15 billion to National Taiwan University to fund biomedical engineering projects and the construction of a hospital for treating cancer.
In June, Gou, who leads the world's largest contract maker of electronic components, reportedly said he would donate NT$100 billion to fund cancer research by scientists in Taiwan and China.
"I will brief him [to try to win] his support for the company [TaiMed Biologics]," Ho Mei-yueh said.
To encourage development of the biotechnology and pharmaceutical industry, the legislature in June passed tthe Biotech and New Pharmaceutical Development Statute (
The new law stipulates that 35 percent of company investment in R&D and personnel training in the two sectors is tax-deductible for the next five years.
If a firm's expenditure on R&D and personnel exceeds its average spending in the previous two years, 50 percent of the extra amount is tax-deductible.
In addition, employees in the industries who receive stock options do not need to pay income tax on their shares.
Government researchers who get permission from the institute where they are employed can also cooperate with private companies to develop new drugs, while researchers can work as consultants at private companies.
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
With an approval rating of just two percent, Peruvian President Dina Boluarte might be the world’s most unpopular leader, according to pollsters. Protests greeted her rise to power 29 months ago, and have marked her entire term — joined by assorted scandals, investigations, controversies and a surge in gang violence. The 63-year-old is the target of a dozen probes, including for her alleged failure to declare gifts of luxury jewels and watches, a scandal inevitably dubbed “Rolexgate.” She is also under the microscope for a two-week undeclared absence for nose surgery — which she insists was medical, not cosmetic — and is
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
Alchip Technologies Ltd (世芯), an application-specific integrated circuit (ASIC) designer specializing in artificial-intelligence (AI) chips, yesterday said that small-volume production of 3-nanometer (nm) chips for a key customer is on track to start by the end of this year, dismissing speculation about delays in producing advanced chips. As Alchip is transitioning from 7-nanometer and 5-nanometer process technology to 3 nanometers, investors and shareholders have been closely monitoring whether the company is navigating through such transition smoothly. “We are proceeding well in [building] this generation [of chips]. It appears to me that no revision will be required. We have achieved success in designing
RSS